Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02370303 · ClinicalTrials.gov registry record
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
A clinical trial, sponsored by Mayo Clinic.
- Completed
- Registry status
- 23
- Enrollment target
NCT02370303: Completed study, sponsored by Mayo Clinic.
NCT02370303 is a clinical trial that has completed, run by Mayo Clinic. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02370303 has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-08 |
| Est. Completion | 2016-07-09 |
What the finished NCT02370303 record still lists
NCT02370303 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02370303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02370303 about?
NCT02370303 is a clinical study titled "A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System". The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in pati...
What is the current status of trial NCT02370303?
This trial is currently completed. The enrollment target is 23 participants. The study started on 2014-08. Estimated completion is 2016-07-09.
Who is sponsoring clinical trial NCT02370303?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia